Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a long-term benefit from these therapies, and many experience off-target, immune-related adverse effects. RCC is also different other ICI-responsive tumors, as it has only modest mutation burden, total neoantigen load does correlate with ICI response...
